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The human 5-HT7 receptor is expressed in both the central nervous system and
peripheral tissues and is a potential drug target in behavioral and psychiatric
disorders. We examined molecular determinants of ligand binding and G protein
activation by the human 5-HT7(a) receptor. The role of several key residues in
the 7th transmembrane domain (TMD) and helix 8 were elucidated combining in
silico and experimental mutagenesis. Several single and two double point mutations
of the 5-HT7(a) wild type receptor were made (W7.33V, E7.35T, E7.35R, E7.35D,
E7.35A, R7.36V, Y7.43A, Y7.43F, Y7.43T, R8.52D, D8.53K; E7.35T-R7.36V, R8.52D-
D8.53K), and their effects upon ligand binding were assessed by radioligand
binding using a potent agonist (5-CT) and a potent antagonist (SB269970). In
addition, the ability of the mutated 5-HT7(a) receptors to activate G protein after
5-HT-stimulation was determined through activation of adenylyl cyclase. In silico
investigation on mutated receptors substantiated the predicted importance of
TM7 and showed critical roles of residues E7.35, W7.33, R7.36 and Y7.43 in
agonist and antagonist binding and conformational changes of receptor structure
affecting adenylyl cyclase activation. Experimental data showed that mutants E7.35T
and E7.35R were incapable of ligand binding and adenylyl cyclase activation,
consistent with a requirement for a negatively charged residue at this position.
The mutant R8.52D was unable to activate adenylyl cyclase, despite unaffected
ligand binding, consistent with the R8.52 residue playing an important role in
the receptor-G protein interface. The mutants Y7.43A and Y7.43T displayed
reduced agonist binding and AC agonist potency, not seen in Y7.43F, consistent
with a requirement for an aromatic residue at this position. Knowledge of the
molecular interactions important in h5-HT7 receptor ligand binding and G protein
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activation will aid the design of selective h5-HT7 receptor ligands for potential
pharmacological use.
Keywords: homology modeling, mutagenesis, molecular dynamics, docking, G protein, adenylyl cyclase
Introduction
The 5-HT7 receptor is a seven-transmembrane spanning
receptor, coupled primarily to the stimulatory G protein (Gs). It
is found in multiple organ systems, such as the cardiovascular
system, CNS and digestive tract. In the central nervous system it
has been proposed to play a role in the action of antipsychotics
and antidepressants and it seems to be involved in regulating
circadian rhythms and thermoregulation, learning and memory,
as well as rapid eye movement (REM) sleep via the modulation
of suprachiasmatic nucleus neurons (Gellynck et al., 2013).
5-HT7 receptor agonists have been suggested in treatment of
dysfunctional memory in age-related decline and Alzheimer’s
disease (Meneses, 2014), as well as treatment of pain, migraine,
schizophrenia, anxiety and cognitive disturbances (Gellynck
et al., 2013; Gasbarri and Pompili, 2014). A possible involvement
in regulation of mood suggests that 5-HT7 is a potential target
for the treatment of depression (Gellynck et al., 2013). In the
periphery the 5-HT7 receptor is found primarily in the smooth
muscle cells of blood vessels (Ullmer et al., 1995), and in the
gastrointestinal tract, where it mediates relaxation of the ileum
and stomach (Prins et al., 1999), and was recently shown to be
important in inflammation (Guseva et al., 2014).
Three human 5-HT7 receptor splice variants (h5-HT7(a),
h5-HT7(b), h5-HT7(d)) have been identified that are structurally
identical except in their predicted intracellular carboxyl terminal
(C-terminal) tail. They have indistinguishable pharmacological
properties and similar abilities to stimulate adenylyl cyclase,
indicating that the C-terminal tail does not influence ligand
binding or G-protein coupling (Krobert et al., 2001). To facilitate
development of selective drugs targeting the h5-HT7 receptor, it
is necessary to understand the molecular interactions involved
in ligand binding to the receptor. Several studies have focused on
the molecular interaction of endogenous serotonin with different
5-HT receptor subtypes. Molecular requirements for serotonin
binding to its receptor include electrostatic interaction between
the receptor and the amino group of the ligand, one hydrogen
bond between donor-acceptor site of the receptor and the hydroxyl
group of serotonin and finally van der Waals interactions.
Mutagenesis studies of serotonin receptors (Ho et al., 1992;
Wang et al., 1993; Boess et al., 1998; Mialet et al., 2000)
suggested that the serotonin amino group makes an electrostatic
interaction with the carboxylate of the highly conserved aspartate
D3.32. This interaction is usually found in biogenic amine
receptors, generally involved in binding of agonists/antagonists
and in receptor activation. And there is evidence that serotonin
hydroxyl groups interact with a donor-acceptor hydrogen bond
residue present in transmembrane domain (TMD) V. These
interactions seem relevant to only some serotonin receptor
subtypes including 5-HT1A, 5-HT2, 5-HT6 and 5-HT4 (Mialet
et al., 2000). The role of D3.32 was not relevant for antagonist
interactions at the 5-HT1A receptor and the role of the hydrogen
bond donor residue of the TMDV was not unambiguously
identified in either 5-HT1A or 5-HT2B receptors (Wang et al.,
2013). These anomalies indicate that the role of individual
residues in molecular receptor-ligand interactions vary among
different serotonin receptor subtypes.
To determine the critical molecular interactions that
mediate ligand binding in the h5-HT7 receptor we used an
experimental and in silico site-directed mutagenesis approach.
Using homology modeling of the β2-adrenergic receptor (pdb:
2RH1; Cherezov et al., 2007), a 3D model of the h5-HT7
receptor was built and stabilized by large scale simulation in
membrane bilayers. We focused on several specific amino
acids, located in the 7th TMD, on the basis of preliminary
modeling considerations, as discussed in the results section.
In order to verify the predicted interactions, several h5-
HT7(a) receptor mutants were generated, expressed and
assessed for ligand binding as well as agonist and antagonist
effects on adenylyl cyclase activity. Our results indicated
that residues E7.35, R7.36 and Y7.43 are critical for ligand
binding, while residue R8.52 plays a key role in G protein
activation.
Methods
Mutation Strategy and Mutagenesis
A preliminary model comparison between the β2-adrenergic and
h5-HT7(a) receptors was performed and the results showed a
strong sequence homology, especially at the level of specific
transmembrane helices. Docking of 5-HT into the orthosteric
binding cavity of our 5-HT7 model revealed a critical role of
residues W7.33, E7.35, Y7.43, R8.53 and D8.54, where some
were similar to that previously reported for the 5-HT7 receptor
based on ligand docking (Kołaczkowski et al., 2006), and for
5-HT1B and 5-HT2B receptors based on crystallization (Wang
et al., 2013). To understand how specific amino acids were
involved in the binding process, determination of the 5-HT7
single point mutations was based on the chemical-physical
characteristics of the specific amino acid with the objective to
change the amino acid charges. In addition, point mutations
were made to remove the aromatic groups to determine their
importance for the interaction with the specific ligands. By site-
directed mutagenesis we generated several clones expressing
h5-HT7(a) receptors with single or double mutated amino
acids.
Molecular Modeling
Molecular dynamics (MD) simulations and docking studies
were carried out using an Intel Core i7 processor, 16 GB RAM,
operating under Linux/Ubuntu 10.04. The homology model
of the h5-HT7 receptor was kindly supplied by Prof. Ingebrigt
Sylte’s group (unpublished data) and built from the crystal
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structure of the β2-adrenergic receptor (pdb: 2RH1; Cherezov
et al., 2007) by SwissModel server.1 Conformations of residues
that differ between the 5-HT7 and β2-adrenergic receptors have
been optimized using the RefineModel macro of ICM (Abagyan
and Totrov, 1994).
The homology model features a disulfide bridge between
TMH3 and extracellular loop 2 (ECL2) which are in accordance
with the template structure. All the wild type and mutants
considered (W7.33V, E7.35T, E7.35R, E7.35D, E7.35A, R7.36V,
Y7.43A, R8.52D, D8.53K and R8.52D-D8.53K) were embedded
in a bilayer of POPC (palmitoyl-oleyl-phosphatidyl choline;
100× 100 Å) and solvated with pre-equilibrated water
molecules in the three-dimensional space (box of water) of
130× 130× 108 Å. The counterions (Na+ and Cl−) were placed
in the proximity of the regions of the protein surface to mimic
an ionic strength of 0.15 mM. Thirty-five nanoseconds of MD
simulations were carried out for all the considered systems
using the NAMD2 software, version 2.9 (Phillips et al., 2005)
with the CHARMM27 force field where all atoms are explicitly
represented and water is characterized by the TIP3P model with
a dielectric constant of 1 (ε) (Jorgensen et al., 1983). All systems
were energy-minimized (conjugate gradient) then gradually
heated up to 300 K with a 2-fs time step and equilibrated
with a 300 K thermal bath for 400 ps. The velocities were
reassigned every 2 ps to achieve complete stability (Berendsen
et al., 1984). Production runs were performed at 300 K. The
SHAKE algorithm with a tolerance of 1 × 10−8 Å was used
to fix the length of the covalent hydrogen bonds (Ryckaert
et al., 1977). Non-covalent interactions were calculated at each
step. To avoid edge effects and treat long-range electrostatic
interactions, periodic boundary conditions and the particle-
mesh-Ewald algorithm with a grid size of 130 × 130 × 108 Å
(Essmann et al., 1995) respectively, were applied to all of the
simulation steps. Non-bonded short-range interactions were
treated by a cutoff value of 10 Å. After minimizing the protein,
the helices were first equilibrated in water with constraints
on the cytosolic side. Next, MD of the helices with added
loops and disulphide bonds was performed. Finally, MD of the
unconstrained domain embedded in a bilayer POPC was carried
out.
The ten mutants of 5-HT7 were constructed based upon the
optimized model obtained as described above, adopting the
mutate plugin of VMD 1.91. The mutants studied were W7.33V,
E7.35A, E7.35D, E7.35R, E7.35T, R7.36V, E7.35T-R7.36V,
Y7.43A, Y7.43T, Y7.43F, R8.52D, D8.53K, and R8.52D-D8.53K.
30 ns of MDs calculation for each mutant was performed, using
computational resources granted from the supercomputing HPC-
CINECA and UK-NSC. The predicted trajectories were analyzed
using the VMD 1.91 software (Humphrey et al., 1996). The average
structures as extracted from the last xyz atomic coordinates (50 ps
for each MD simulation) were used as input file for docking.
Semiflexible docking was carried out by the molecular
docking algorithm MolDock Optimizer and the scoring function
MolDock [GRID] as implemented in the Molegro Virtual
Docker software, version 6 (Thomsen and Christensen, 2006).
1http://swissmodel.expasy.org/
Only torsion angles in the side chains were modifed during the
minimization; all other properties, including bond lengths and
backbone atom positions, were held fixed, and a new receptor
conformation was generated for each pose after each docking
calculation. The 10 runs for each molecule were carried out
with a population size of 50, maximum iteration of 2000, scaling
factor of 0.50. 5-carboxamidotryptamine (5-CT) and SB269970
structures were built and minimized by the software SYBYL-X
1.3.2
Site-Directed Mutagenesis
All mutant h5-HT7(a) sequences used in this work were
obtained by site-directed mutagenesis of the coding region of
the human h5-HT7(a) sequence cloned in pcDNA3.1 vector
(Krobert et al., 2001). We used the QuikChange® Site-Directed
Mutagenesis kit containing a PfuTurbo DNA polymerase
(Agilent). All mutated sequences were confirmed by DNA
sequencing. Using this strategy we generated a set of h5-HT7(a)
clones carrying a single mutation at the following positions:
W7.33V, E7.35T, E7.35R, E7.35D, E7.35A, R7.36V, Y7.43A,
Y7.43F, Y7.43T, R8.52D, D8.53K. We also generated h5-HT7(a)
clones with the double mutations E7.35T-R7.36V and R8.52D-
D8.53K.
Expression of Wild-Type and Mutant Human
5-HT7(a) Receptors and Cell Culture
The human 5-HT7(a) receptor mutants obtained were expressed
in QBI-HEK293 cells which were grown in Dulbecco’s
modified Eagle’s medium (DMEM; GIBCO) with 10% fetal
bovine serum (BioWhittaker) and penicillin (100 U/ml)
and streptomycin (100 µg/ml). Cells were transiently
transfected with wild-type and mutated plasmid DNA
using LIPOFECTAMINE™—LTX reagent (Invitrogen™) and
7.5 µg DNA per 150 mm dish and a serum-free medium
(ULTRAculture, BioWhittaker; because serum contains high
concentration of serotonin) supplemented with L-glutamine
(2 mM), penicillin (10000 U/ml) and streptomycin (10000
U/ml).
Membrane Preparation
Membrane preparations from transiently transfected QBI-
HEK293 cells containing the mutated receptors were prepared
48 h after transfection as described previously (Krobert et al.,
2001).
Binding Assays
The receptor expression level of QBI-HEK293 cells expressing
mutated h5-HT7(a) was determined by radioligand binding.
Binding assays were performed in 96-well, round-bottom
microtiter plates with total reaction volume of 50 µl, containing
the indicated concentration of ligand ([3H]5-CT (serotonin
agonist) or [3H]SB269970 (serotonin antagonist)) as previously
described (Krobert et al., 2001). Specific binding was defined
as the difference between total binding and non-specific
2http://www.certara.com
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binding (obtained in the presence of 10 µM 5-HT). G-protein-
coupled receptors may exist in different conformations, such
as low and high affinity states. In the presence of excess
GTP most receptors will exist in the low affinity state.
To avoid bias due to unpredictable ratios between the two
affinity states, GTP (100 µM) was included in the assay
mix.
Adenylyl Cyclase Assays
Adenylyl cyclase activity was measured by determining
conversion of [α-32P]ATP to [32P]cAMP in membrane
preparations as previously described (Krobert et al., 2001).
Briefly, adenylyl cyclase activities were measured on 10 µl
aliquots in a final volume of 50 µl in the presence of 0.1 mM
[α-32P]ATP, 4 mM MgCl2, 20 µM GTP, 1 mM EDTA, 1 mM
[3H]cAMP, 1 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma),
a nucleoside triphosphate regenerating system and additives
(FSK (100 µM), 5-CT, 5-HT and SB269970). The samples
were incubated for 20 min at 32◦C. Cyclic AMP formed was
quantified by the double column chromatography system on
Dowex 50 cation exchanger and on neutral aluminium oxide
(Alumina) columns. The recoveries of each sample through
the columns are monitored by adding [3H]cAMP to the
assay mix, thus eliminating individual differences between the
columns.
Binding and Adenylyl Cyclase Data Analysis
Binding and adenylyl cyclase data were analyzed by non-linear
regression using Microsoft Excel 2007 with the Solver add-in, as
described (Krobert et al., 2001).
Western Blot
Lysates of membrane preparations were separated by SDS-
PAGE and electroblotted as described (Norum et al., 2005).
The membranes were incubated overnight at 4◦C with a 1:200
dilution (v/v) of rabbit anti-5-HT7R (Oncogene Research
Products, Boston, MA) in PBS containing 5% (w/v) non-fat
dry milk and 0.05% (v/v) Tween 20. Thereafter, the blots
were incubated with a 1:5000 dilution (v/v) of HRP-linked
anti-rabbit IgG (Amersham ECL™-HRP Linked Secondary
Antibodies, GE Healthcare). The immobilized HRP-conjugated
secondary antibodies were visualized with the LumiGLO
Chemiluminescent Substrate (KPL, Inc.) and visualized with a
UCP Sensicam (UVP Inc., CA, USA).
FIGURE 1 | Root Mean Square Deviation (RMSD) is referring to the backbone of the four mutants E7.35T, E7.35R, R8.52D and D8.53K.
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Results
Modeling
MD simulations of the mutants of 5-HT7 were performed
in order to obtain a reliable structure for the subsequent
docking calculation. After about 30 ns of equilibration root
mean square deviation (RMSD) profiles were analyzed for
all mutants to verify the backbone stability and perform
docking analysis. All RMSD curves are steady along the whole
equilibration phase and no noteworthy oscillations were
observed, demonstrating that all structures were stabilized
and equilibrated by 35 ns of MD. Figure 1 shows the trend of
RMSD for backbone atoms of the mutated receptors E7.35T,
E7.35R, R8.52D and D8.53K. All analyzed models showed a
high structural rigidity; for all models the RMSD was about
0.165 Å.
In addition, in Figure 2, the secondary structures of the
models were plotted over time, in order to verify that the
predicted secondary structure does not change significantly.
The backbone of the seven trans-membrane domains seems
to be stable in helix conformation during the simulation. On
the other hand, residues of the extracellular loops appear to
be more flexible, and they do not have a stable conformation.
At the end of 30 ns of equilibration, our model consists of
seven transmembrane helices (Figure 2) and a large cavity
defined by the helices III, V, VI and VII, in accordance with
Wang et al. (1993). Comparison of our 5-HT7 model with the
X-ray structure of 5-HT1B (4IAQ) (Wang et al., 2013) and
5-HT2B (4IB4) (Wacker et al., 2013) receptors, confirms that
the main folding pattern of our model appears to be consistent
with experimental data, as reported in panel A of Figure 3.
While the three structures here compared have slightly different
primary sequences (e.g., T6.46 in 5-HT7, M6.46 in 5-HT2B
and A6.46 in 5-HT1B), the same region with different amino
acids has the same spatial orientation of the side chains, as
evidenced in Figure 3B. Particularly, glutamic acid is conserved
in all the models, along with its orientation. Moreover, in
our model a formation of a hydrogen bond between T7.35
and R6.58 is observed, as discussed later in the discussion
section, which should play a role in ligand binding. All the data
indicate that our models appear good candidates for further
study.
Docking results have been summarized in Table 1. All
the mutants are predicted to bind both the agonist 5-CT and
the antagonist SB269970. Tables 2, 3 list the favorable and
unfavorable interactions of the two reference molecules with
the wild type and mutant receptors. Overall, the antagonist
(SB269970) forms a higher number of positive interactions and
no unfavorable steric interactions that allow the formation of
more stable complex (more negative docking score) than the
FIGURE 2 | Secondary structure for the mutants E7.35T, E7.35R, R8.52D and D8.53K calculated over the molecular dynamic (MD) trajectory. Red
represents helix conformation, blue represents turn conformation, white represents random coil conformation.
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FIGURE 3 | (A) Superimposition of 5-HT7 after 30 ns of equilibration (red) with 5-HT1B (blue) (Wang et al., 2013) and 5-HT2B (yellow) (Wacker et al., 2013).
(B,C) Main chain of the three receptors represented as stick and aminoacid residues as lines.
agonist. Mutation of E7.35 to Asp, Thr and Arg were predicted
to produce better binding compared to the wild type protein,
while mutation of E7.35 to Ala was predicted to maintain high
binding capacity. On the contrary, mutation of R8.52 to Asp
was predicted to produce weaker binding. Only mutant D8.53K
was predicted to show slightly lower binding. In this case the
increased steric hindrance of the mutations plays a key role in
binding properties.
Characterization of Human 5-HT7(a) Mutants
Ligand Binding
The mutant receptors were examined by comparing the
binding properties and ability to activate adenylyl cyclase
(cyclic AMP production), using transiently transfected QBI-
HEK293 cells. The affinities of the agonist (5-CT) and the
antagonist (SB269970) determined from saturation binding
experiments with up to 3 nM of [3H]5-CT and up to 2.5 nM
[3H]SB269970 varied from being not modified, reduced or, in
some mutants, no specific binding was detected. The receptor
TABLE 1 | MolDock score (a.u.) from docking analysis of wild type and
mutant receptors with 5-CT and SB269970.
5-CT SB269970
5-HT7(a) −93 −132
W7.33V −95 −127
E7.35T −102 −129
E7.35R −103 −151
E7.35D −98 −127
E7.35A −100 −124
R7.36V −109 −144
Y7.43A −100 −126
R8.52D −92 −111
D8.53K −89 −119
R8.52D-D8.53K −114 −119
density of all the analyzed mutants was only slightly reduced in
a subset of mutants, so receptor density is unlikely to account
for changes in affinity (shown in Table 4). In addition, the
ability to activate AC was either unmodified or reduced in
the mutated receptors compared to wild-type (Table 5). Most
importantly, the mutagenesis studies revealed critical roles of
residues E7.35, R7.36 and Y7.43 in ligand binding and R8.52 in
activation of AC.
Initially, E7.35 was mutated to Thr to remove the negative
charge in this part of the receptor and this new receptor showed
a complete lack of ability to bind either agonist or antagonist.
To understand which kind of interaction is critical in this
part of the receptor for the ligand-receptor-interaction, other
mutations were performed at E7.35: (1) to Asp (E7.35D) to
understand the importance of amino acid charge; (2) to Ala
(E7.35A) to test if the length of the side chain is important
for ligand binding; and (3) to Arg (E7.35R) to determine if
there are electrostatic interactions involved. These new mutants
(E7.35D, E7.35A, E7.35R) were analyzed as above in the binding
assays. While the E7.35R mutant receptor was completely
unable to bind either agonist or antagonist, the E7.35A mutant
displayed reduced binding affinity for agonist, but not for
antagonist, and the E7.35D mutation did not change the ability
of the receptor to bind any ligands (Table 4). Mutation of
the neighboring residue, R7.36V, resulted in decreased binding
affinity for agonist only and a reduced receptor expression.
The double mutant E7.35T-R7.36V was unable to bind any
ligands.
The mutation R8.52D, where the positive charge was replaced
by a negative one, did not alter the affinity for 5-CT or SB269970
(but the receptor expression was significantly reduced), neither
did the mutation D8.53K nor the double mutant R8.52D-
D8.53K. Another TMH7 mutation evaluated was Y7.43A,
where the aromatic group of residue Y7.43 was replaced with
the non-polar Ala residue. This mutation caused a significant
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TABLE 2 | List of favorable and unfavorable interactions after docking between SB269970 and the target molecules.
Protein H bond interactions Hydrophobic interactions Favorable steric interaction
Wild type Cys231, Ile233, E7.35,
T2.64, R7.36
I3.29, Leu232, Leu236, L7.39, F2.60, F3.28 (pi stacking), V2.61, Val230 R6.58, S6.55
E7.35A T4.57, S5.42, Gln235 A5.46, I4.56, Ile233, L4.61, F5.47, F6.52, P4.60, T3.37, Trp221, V3.33 D3.32, C3.36, T5.39, T5.43
E7.35D D3.32, S6.55 I3.29, Ile233, Leu232, L4.61, F3.28, F6.51, F6.52 (pi-stacking), T5.43
(t-stacking), W6.48, V3.33
R6.58, C3.36, Gln235
E7.35R W6.48, Y7.43 A5.46, I3.29, Ile233, Leu232, L7.39, F3.28, F6.44, F6.51, F6.52,
W6.48, Y7.43, V2.53, V3.33
D3.32, C3.35, C3.36, Cys231
E7.35T I4.56, T5.43 A5.46, I4.56, Ile233, L4.61, L7.39, F5.47, F6.51, F6.52, T3.37, T4.57,
T5.39, T5.43, W6.48, V3.33, V5.45
D3.32, C3.36, Gln235, S5.42
R8.52D C3.36 A5.46, L6.49, L7.39, M3.34, F5.47, F6.44, F6.51, F6.52 (t-stacking),
T3.37, T5.43, W6.48 (t-stacking), V3.33
D3.32
V7.33W C3.36, D3.32 A5.46, I3.29, I3.40, L7.39, F5.47, F6.51, F6.52, T3.37, T4.57, T5.43,
W6.48 (pi-stacking), Y7.43, V2.53, V3.33
S5.42, S6.55
Y7.43A S6.55 I3.29, Ile233, Leu232, L7.39, F3.28, F6.51, F6.52 (pi-stacking), W6.48
(t-stacking), V3.33
R6.58, D3.32, C3.36, S6.55
R7.36V G7.42 A2.49, G7.42, L7.39, L7.41, F5.47, F6.51, F7.38, W6.48, W7.40,
Y7.43, V2.53
D3.32, C3.35, C3.36, C6.47, S3.39,
S7.46
D8.53K F6.52 A5.46, Ile233, I5.40, L4.61, F4.62, F6.52, P4.60, P6.59, Y5.38, Y5.48,
V3.33
Gln223, Gln235, S5.42, S6.55, T4.57,
T5.39, T5.43, T6.56
R8.52D-D8.53K T4.57, T3.37 A5.46, I3.40, I4.56, L7.39, F6.51, F5.47, F6.52, T5.39, W6.48, Y7.43,
V3.33
D3.32, C3.36, S5.42, T3.37, T4.57,
T5.43
AAs which are part of the helices are numbered according to Ballesteros-Weinstein nomenclature (Ballesteros and Weinstein, 1995).
TABLE 3 | List of favorable and unfavorable interactions after docking between 5-CT and the target molecules.
Protein H bond interactions Hydrophobic interactions Favorable steric interactions
Wildtype(1) I3.29, D3.32, Y7.43,
Cys231
A3.30, Ile233, Leu232, L7.39, F3.28 (stacking), V2.61, V2.57, V3.33 R6.58, E7.35
E7.35A I4.56, V3.33, Gln235,
T3.37
A5.46, Ile233, L4.61, P4.60, F6.52, T5.43, Trp221, Y5.38, V3.33,
V5.45
S5.42, T4.57
E7.35D S6.55, Cys231, I3.29 A3.30, Leu232, Ile233, F3.28 (t-stacking), F6.51, V3.33, Val230 R6.58, D3.32, Gln235
E7.35R D3.32, Y7.43 A3.30, I3.29, Ile233, Leu232, L7.39, F3.28, F6.51, F6.52, W6.48,
Y7.43, V3.33
Cys231
E7.35T A5.46, T5.43, Gln235,
D3.32
A5.44, A5.46, I3.40, M3.34, F5.47, F6.52 (t-stacking), V3.33 C3.36, S5.42, T3.37, T5.39
R8.52D T4.57, I3.29 A3.30, I3.29, Ile233, L4.58, L4.61, P4.60, S5.42, Trp221, Y5.38, V3.33,
Val225
Asn224, Gln223, Gln235, T4.57
V7.33W D3.32, T5.39, T5.43,
T3.37
A5.46, I3.40, L4.61, F5.47, F6.52, Y5.38, V3.33 C3.36, Gln235, S5.42, T3.37, T4.57,
T5.39, T5.43
Y7.43A S6.55, T5.43 A5.46, Ile233, F5.47, F6.52, P6.59, Y5.38 (t-stacking), V3.33 Gln235, Ser234, S5.42, S6.55, T4.57,
T5.39, T6.56
R7.36V(2) L7.39, W6.48, G7.42,
S7.46
G7.42, L6.49, L7.39, L7.41, F5.47, F6.51, F6.52, F7.38, W6.48,
W7.40, Y7.43 (t-stacking), V2.53
C3.36, C6.47, D2.50(electro-static
interaction), S7.46
D8.53K Gln235, Ser234 Ala222, Gly220, I3.29, Ile233, L4.61, Leu232, F4.62, P4.60, Trp221,
Y5.38, Val225
Asn224, Gln223, Gln235, Ser234,
T5.39
R8.52D-D8.53K A5.46, T4.57, I4.56,
S5.42, T3.37
A5.46, I3.40, I4.56, F5.47, F6.52, V3.33 C3.36, S5.42, T3.37, T4.57, T5.39,
T5.43
AAs which are part of the helices are numbered according to Ballesteros-Weinstein nomenclature (Ballesteros and Weinstein, 1995). (1) Unfavorable electrostatic
interactions with R6.58 and Lys229. (2) Unfavorable electrostatic interactions with R6.58. Favorable electrostatic interaction with D2.50.
reduction in agonist binding affinity and a possible reduction in
antagonist binding affinity, in addition to a reduction in receptor
expression. To determine if the aromatic group or OH-group
was involved in the changes elicited by mutation Y7.43A, mutant
receptors Y7.43F and Y7.43T were constructed. Preliminary data
indicate that Y7.43T showed a reduction in ligand potency and
receptor expression, whereas Y7.43F was without effect upon
ligand binding.
Effect upon Adenylyl Cyclase Activation
We next examined the effect of the different mutations within
TMH7 of the h5-HT7(a) receptor on the transductional response
(G protein activation) by measuring their ability to activate
adenylyl cyclase (AC). As shown in Table 5 and Figure 4,
the W7.33V, E7.35D, R7.36V, Y7.43A, and D8.53K mutated
receptors stimulated AC activity with the same potency as the
wild-type receptor. A possible higher affinity for the antagonist
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TABLE 4 | Binding properties of wild-type and mutant 5-HT7(a) receptors expressed in QBI-HEK293 cells.
Mutant [3H]5-CT [3H]SB269970
pKd Bmax (pmol/mg protein) pKd Bmax (pmol/mg protein)
5-HT7(a) 9.51 ± 0.05 2.00 ± 0.27 9.51 ± 0.57 1.79 ± 0.27
W7.33V 9.57 ± 0.11 1.94 ± 0.09 9.30 ± 0.07 1.92 ± 0.21
E7.35T No specific binding No specific binding
E7.35R No specific binding No specific binding
E7.35D 9.17 ± 0.09 2.14 ± 1.01 9.50 ± 0.06 2.08 ± 0.63
E7.35A 8.74 ± 0.32 * 1.14 ± 0.03 9.41 ± 0.01 1.36 ± 0.15
E7.35T-R7.36V No specific binding No specific binding
R7.36V 8.17 ± 0.54 * 0.66 ± 0.37 † 9.77 ± 0.03 0.26 ± 0.06 †
Y7.43A 8.55 ± 0.29 * 0.21 ± 0.09 † 8.98 ± 0.34 0.27 ± 0.16 †
Y7.43T 8.55 0.21 8.56 0.41
Y7.43F 9.21 2.78 9.62 2.52
R8.52D 9.17 ± 0.04 0.53 ± 0.06 † 9.09 ± 0.01 0.46 ± 0.07 †
D8.53K 9.30 ± 0.07 1.22 ± 0.15 † 9.25 ± 0.09 1.09 ± 0.04
R8.52D-D8.53K 9.57 ± 0.09 1.20 ± 0.07 9.53 ± 0.10 1.19 ± 0.07
Wild-type (5-HT7(a)) and mutant receptors were transiently transfected in QBI-HEK293 cells. Membranes were subjected to saturation binding analysis using [3H]5-CT and
[3H]-SB269970 as selective ligands. Affinity values are presented as pKd values (−log Kd). Data shown are average ± SEM of 3–5 experiments, except for Y7.43T and
Y7.43F (n = 1). * − P < 0.05 One-way ANOVA with Dunnett’s multiple comparisons test vs. wild-type. † − P < 0.05 One-way ANOVA with Dunnett’s multiple comparisons
test vs. wild-type within experiments.
TABLE 5 | Activation of adenylyl cyclase (AC) by the agonists 5-CT and
5-HT and inhibition of 10 µM 5-HT-stimulated AC by the antagonist
SB269970.
Mutant pEC50 pKi
5-CT 5-HT SB269970
5-HT7(a) 7.82 ± 0.07 7.06 ± 0.03 8.90 ± 0.10
W7.33V 7.99 ± 0.16 7.27 ± 0.12 8.76 ± 0.31
E7.35T N.D. N.D. N.D.
E7.35R N.D. N.D. N.D.
E7.35D 7.67 6.85 9.12
E7.35A 7.39 6.48 8.77
E7.35T-R7.36V N.D. N.D. N.D.
R7.36V 7.89 6.69 9.67
Y7.43A 7.62 ± 0.28 6.76 ± 0.04 * 8.13 ± 0.03 *
Y7.43T 7.45 5.98 7.28
Y7.43F 8.15 7.23 8.98
R8.52D N.D. N.D. N.D.
D8.53K 7.69 ± 0.06 6.81 ± 0.10 8.59 ± 0.13
R8.52D-D8.53K 6.91 ± 0.07 6.28 ± 0.08 9.15 ± 0.16
Potency values are presented as pEC50 (−log EC50) values for agonists and pKi
(−log Ki) values for antagonists, calculated by the method of Cheng and Prusoff
(1973). Data shown are average ± SEM of 1–8 experiments. N.D., no AC activity
detected. *p < 0.05 One-way ANOVA with Dunnett’s multiple comparisons test vs.
wild-type.
SB269970 of the R7.36V mutant receptor measured in AC
assays (Figure 4; Table 5) was not supported by binding data
(Table 4) and therefore not investigated further. Particularly
interesting was the finding that the R8.52D mutant which
displayed unaltered binding affinity for both agonist and
antagonist, was not able to activate AC constitutively (no effect
of SB269970), or by either of the agonists 5-CT or 5-HT
(Table 5). In contrast, the Y7.43A mutant displayed a lower
binding affinity for 5-CT, a lower potency on AC for 5-HT
and SB269970, but no change in potency to activate AC for
5-CT (Table 5). In line with the lack of binding, the mutants
E7.35T and E7.35R showed no ability to activate AC, whereas
the conservative mutation E7.35D showed no change in AC
activation and the E7.35A mutant activated AC with reduced
potency.
Lack of Binding not due to Lack of Receptor
Expression
To determine if the complete inability of the E7.35T and E7.35R
mutants to bind the radioligands [3H]5-CT and [3H]SB269970
resulted from the absence of receptor expression, we determined
if these receptors were in fact expressed by subjecting membrane
preparations to SDS-PAGE and determining 5-HT7 expression
using a polyclonal antibody directed against the N-terminus
of the h5-HT7 receptor. In those receptors analyzed (even in
mutants with reduced or absent radioligand binding), a protein
band of about ∼50 kDa, corresponding with the size of the
h5-HT7 receptor, was detected, whereas in non-transfected
control cells no band was detected (data not shown). These data
indicate that the absence of ligand binding of the various mutant
receptors does not result from a lack of receptor expression
despite displaying an absence of radioligand binding.
Discussion
GPCRs are challenging targets in drug design (Overington
et al., 2006). Despite the recent surge of GPCR structural
data, structures have only been determined for a minor
fraction of GPCRs. Therefore, in silico tools are key to
obtain structural information to integrate and rationalize the
design of experimental studies of receptor-ligand interactions.
Homology modeling has been successfully applied for several
different GPCRs (see Sandal et al., 2013 and references therein).
Combining in silico with experimental tools can lead to accurate
structural characterization and accelerate drug design. In this
work, the mechanism of molecular recognition between the
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FIGURE 4 | Ability of mutant receptors to activate adenylyl cyclase.
Adenylyl cyclase (AC) activity in response to increasing concentrations of
5-HT (A) or 5-CT (B) in membranes from QBI-HEK293 cells transiently
expressing the wild-type (WT) or indicated mutant receptors. In (C) the ability
of increasing concentrations of SB269970 to antagonize 10 µM 5-HT was
determined. AC activity was measured as described under Materials and
Methods, and the data shown are representative of those obtained from 1–3
independent experiments.
h5-HT7 receptor and ligands was investigated through in silico
molecular docking and well-established in vitro experimental
approaches.
The modeling data predicted that the residue E7.35 of the
wild type was relevant for ligand binding. In particular, this
residue located in the TMH7 is involved in the formation of a
three-member salt bridge with R7.36 and R6.58. Therefore, we
focused our attention on this residue and performed single point
mutagenesis in order to evaluate the effect of specific amino
acids on the binding affinity of the receptor. The chosen mutants
E7.35T, E7.35R, E7.35A, E7.35D were created by site-directed
mutagenesis and analyzed with radioligand binding assays and
the ability to activate AC.
The ability to bind both the agonist (5-CT) and antagonist
(SB269970) radioligand was completely abolished in the E7.35T
mutant, despite expression of the mutant receptor as determined
by Western analysis. An analysis of the MD trajectory suggests
that the inability to activate the receptor may result from the
formation of a H bond between T7.35 and R6.58 in the E7.35T
mutant. Possibly, this H bond acts as a locked gate preventing
the entry of the ligands to the binding cavity (Figure 5).
Likewise, no specific binding of either agonist or antagonist
ligands was observed in the mutant E7.35R. The MD analysis
of E7.35R suggests that the guanidine side chain of R7.35 in
the E7.35R mutant moves towards the guanidine side chain of
R6.58 blocking the entrance to the orthosteric pocket of the
protein (Figure 6). Consistent with the lack of binding, the
E7.35T and E7.35R mutant receptors were unable to activate
adenylyl cyclase activity (Figure 4; Table 5). Not surprisingly,
the conservatively changed mutant E7.35D receptor, maintaining
the charged residue, behaved essentially as the WT receptor
both regarding binding and AC activation, consistent with the
important role of the electrostatic interactions with this residue.
Also consistent with this was the finding that the E7.35A
mutated receptor, replacing Glu with the nonpolar Ala, showed
reduced binding affinity to both agonist (5-CT) and antagonist
(SB269970) radioligand (Table 4), and was still able to activate
AC, but with reduced potency in line with the reduced binding
affinity (Table 5).
The MD analysis showed that another residue was important
in the interaction with the ligands: R7.36. The Arg was changed
to Val (R7.36V) and the mutation reduced the affinities of agonist
(5-CT), but not for antagonist (SB269970) radioligand (Table 4).
But the mutant receptor displayed 5-CT-stimulated AC activity
with essentially the same properties as the wild-type receptor
(Table 5; Figures 4A–C). MD simulations indicated that the
R7.36 is involved in a network of interactions. This residue
formed an electrostatic interaction with D2.65, which is partially
instable (0.8% of whole simulation), due to the formation, as
said before, of a three-member salt bridge R7.36-E7.35-R6.58.
Consequently, the extracellular part of TMH7 is constrained by
two salt bridges to TMH2 and TMH6.
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FIGURE 5 | (A) Overlap of R7.35 and R6.58 in the mutant E7.35R. The backbone is shown in cartoon representation and the residues are indicated in stick format.
(B) Distance between the two guanidine groups of R7.35 and R6.58 measured over the MD trajectory.
FIGURE 6 | (A) H bond between T7.35 and R6.58 in the mutant E7.35T. The backbone is shown in cartoon representation and the residues are indicated in stick
format. (B) Distance between the oxygen atom of T7.35 and hydrogen aminic atom of R6.58 measured over the MD trajectory.
The release of this ionic lock could be a key step in
receptor activation. In order to test this hypothesis, charge-
neutralizing mutations of E5.67 and of D3.49 were made in the
β2-adrenergic receptor (Ballesteros et al., 2001). Experimental
data by Ballesteros et al. (2001), together with the high-resolution
structure of rhodopsin (Palczewski et al., 2000) suggest that ionic
interactions between D/E3.49, R3.50, and E6.30 may constitute a
common switch governing the activation of many rhodopsin-like
G-protein-coupled receptors. In addition, semi-flexible docking
calculations were performed at the binding cavity defined by
the residues from the 3rd, 5th, 6th, 7th helices and the ECL2,
including an orthosteric pocket embedded in the 7TM core and
a long binding pocket close to the extracellular site. The binding
mode is in accordance with that recently reported for the crystal
structure of the h5-HT1B G-protein-coupled receptor bound to
ergotamine or dihydroergotamine, which are accommodated at
the orthosteric pocket and an extended binding pocket close
to the ECL2, respectively (Wang et al., 2013). The residues
belonging to the architecture of this pocket are conserved in
5-HT receptors.
The movements of transmembrane segments (TMs) III and
VI at the cytoplasmic side of the membrane play an important
role in the activation of G-protein-coupled receptors. There is
evidence for the existence of an ionic lock that constrains the
relative mobility of the cytoplasmic ends of TM3 and TM6 in
the inactive state of the β2-adrenergic receptor (Ballesteros et al.,
2001). The highly conserved R3.50 at the cytoplasmic end of TM3
interacts both with the adjacent D3.49 and with E6.30 at the
cytoplasmic end of TM6. Such a network of ionic interactions
has now been directly supported by the high-resolution structure
of the inactive state of the β2-adrenergic receptor (Dror
et al., 2009) and would serve to constrain the receptor in the
inactive state.
The R8.52D mutant receptor showed a different behavior:
although the receptor displayed normal affinity for ligands
and a significantly reduced expression (Table 4), the receptor
was unable to activate adenylyl cyclase (Table 5). The MD
data showed that this residue pointed toward the water during
simulation; its position was at the base of helix VII and near
the G protein binding domain. We examined the next residue
D8.53 to better understand the importance of this region. We
changed the Asp to Lys and found that the affinity of both agonist
and antagonist ligands for the D8.53K mutant was similar to
that observed for the wild-type receptor. A similar result was
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obtained in the adenylyl cyclase assays, where the D8.53K mutant
receptor activated the enzyme with the same efficiency as the
wild-type receptor. However, the D8.53K mutation was able to
rescue the ability of the R8.52D-mutated receptor to activate
AC, since both 5-CT and 5-HT were able to stimulate adenylyl
cyclase activity through the double mutated R8.52D-D8.53K
receptor with essentially unchanged potency (Table 5) and only
a decrease in the efficacy (not shown) compared with the wild-
type receptor. Thus the mutagenesis data on the R8.52 residue
might be explained by the R8.52D mutation destroying the
receptor-G protein interface, possibly by removing the positive
charge.
To better understand which kind of interactions are
important to bind the specific ligands, to activate the receptor
and the downstream pathway, we analyzed the aromatic residues
W7.33 and Y7.43. The W7.33 was replaced with Val and Y7.43
with Ala. The mutated receptor W7.33V didn’t change the
affinities for 5-CT and SB269970 ligands and stimulated cAMP
production with the same efficiency as the wild-type receptor.
The Y7.43A mutant showed a significantly reduced affinity
of agonist binding, whereas the reduction in antagonist binding
did not reach significance. Kołaczkowski et al. (2006) reported
this amino acid to be involved in formation of hydrogen bond
with ligands. The two mutants Y7.43F and Y7.43T were designed
to assess if the aromatic or the OH-group is involved in the
binding process. Based on preliminary data, only the mutant
Y7.43T showed a reduction in the ability to bind both the ligands.
No changes were observed for the mutant Y7.43F (Table 4). The
data are generally in agreement with that for AC activation and
antagonism (Table 5). These experimental data were explained
by MD simulations, which pointed out that another highly stable
salt bridge is formed between Y7.43 and D2.65 in the TMH2 of
the 5-HT7 receptor.
The actions of ligands at receptors depend on the affinity
for the receptor and the activation of a signaling system,
termed efficacy, which is positive for agonists as a result of
conformational changes. While some of the above mentioned
mutations do not seem to affect ligand recognition, they may still
prevent or reduce receptor activation and G protein coupling,
illustrating independent contributions of these residues in the
WT to stabilizing the bound ligands and/or formation of a
ligand-induced active state of the receptor (Osaka et al., 1998;
Strange, 2008).
Conclusion
Based on the above reported findings there seems to be a non-
ionic lock between helix III and helix VI in the 5-HT7 receptor.
However, when the salt-bridge between D3.49 and R3.50 is
broken a new one is formed between R3.50 and S2.39. The active
and inactive states of the 5-HT7 receptor are characterized by
D3.49-R3.50 and R3.50 and S2.39 salt bridges, respectively. The
mutant R8.52D in helix VIII lacks cyclase activation. This residue
points toward the water during simulation; its position is at
the base of helix VII and near the G protein binding domain.
Thus, the mutagenesis data on this residue might be explained
by destruction of the receptor-G protein interface, and we can
assume that the charge is important.
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